Asensus Surgical (NYSEMKT: ASXC)
Some price data may be temporarily unavailable.
Asensus Surgical Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Asensus Surgical Company Info
Asensus Surgical, Inc. is a medical device company, which digitizes the interface between the surgeon and the patient to improve minimally invasive surgery through digital laparoscopy. It enables the use of advanced capabilities like augmented intelligence, connectivity and robotics in laparoscopy, and addresses the current clinical, cognitive, and economic shortcomings in surgery. The Senhance Surgical System features a machine vision system for use in robotic surgery, which is powered by the new Intelligent Surgical Unit (ISU) that enables augmented intelligence in surgery and brings the benefits of digital laparoscopy to patients around the world while staying true to the principles of value-based healthcare. The company was founded by William N. Starling on August 19, 1988 and is headquartered in Durham, NC.
News & Analysis
Is This Rapidly Growing Surgical Robotics Stock a Buy?
Asensus Surgical's Senhance Surgical System is being more widely adopted by surgeons.
Why Asensus Surgical Stock Is Moving Up Today
Earnings results for the third quarter look great, until you peek under the hood.
Is This Surgical Robotics Company a Cheap Buy Now?
After Asensus Surgical joined the Russell 2000 index last month, the stock climbed higher but has since fallen back to earth.
Why Asensus Surgical Stock Is Soaring Today
An analyst initiated a buy recommendation for the surgical-robot company.
Is TransEnterix a Good Stock to Buy Now?
Shares of the robotic surgical-system manufacturer are soaring, but can this company become the next Intuitive Surgical?
These 2 Growth Stocks Can Become Money Machines in the Next 5 Years
One robotic surgery company and one cybersecurity specialist are bound to impress in the long run.
Why TransEnterix Stock Surged Today and Then Gave Up All its Gains
The robotic surgery specialist is helping to enhance the capabilities of surgeons, but its shares may have come too far, too fast.
Here's Why TransEnterix Fell Hard on Thursday
The Senhance Surgical System's launch isn't progressing nearly as well as investors had hoped.
Valuation
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.